FiercePharma is a news organisation based in Newton, Massachusetts, that analyses and reports on a variety of news from the pharmaceutical industry, including tracking of regulatory approvals, payer negotiations, manufacturing, marketing, patent fights, government investigations and regulation and M&A deals.

Mixed feelings? Havas tackles the emotional motivations behind healthcare decisions with new agency

Emotion is a strong decision-driver, particularly in healthcare. It’s so important, in fact, that Havas Health & You has launched an entire agency to focus on it. Using advanced algorithms and analysis, the new Havas Health Plus aims to understand and address the emotional triggers—what makes people do or choose something—to build […]

Regeneron's Eylea still sitting pretty even after new data from would-be rivals Roche, Novartis: analyst

Regeneron executives don’t see a reason to worry about Eylea’s growth prospects, despite some dire predictions over the past several months. And after this weekend’s data presentations from potential competitors, some analysts agree. Leerink Partners analyst Geoffrey Porges, for one, wasn’t impressed by Novartis’ brolucizumab or Roche’s RG7716 at Saturday’s Bascom Palmer […]

Pharma and AI: Help doctors with AI assistants but don’t try to replace them

Dr. Robot gets a thumbs down from patients, according to new research from Syneos Health. Despite tech and investor enthusiasm, along with media headlines highlighting artificial intelligence in healthcare, patients are adamant that artificial intelligence should not replace doctors. Sixty percent say “no thanks” to AI doctors, and only 16% of those surveyed […]

Lilly, Livongo team up for real-world diabetes research, aiming for better results in an outcomes-oriented market

There’s a new tech partnership in diabetes, this time between Eli Lilly and Livongo. And it’s looking to tap real-world data to deliver better results for patients with Type 1 and Type 2 versions of the disease. The partners aim to help patients adopt healthier habits and save money, improving outcomes that are not […]

GlaxoSmithKline's upward trajectory faces a £750M knock with Advair copies. What can fill the gap?

Amid a Street-beating fourth-quarter report, GlaxoSmithKline quantified the hit that it’s been bracing for: Advair generics. If copycats launch midyear, as their makers hope, Glaxo figures its lead drug will lose half its U.S. sales. Mylan and Novartis’ Sandoz business are first in the wings with their Advair versions, biding their […]